Neel Shah, MD, MMP shares his thoughts on the ARRIVE Trial. Dr. Shah is recognized as an innovative leader in maternal-infant health and a well-respected expert on effective methods for reducing the cesarean rate in the U.S.
Henci Goer examines the just-released ARRIVE Trial to determine if there is new information compared to the study abstract that raises more questions or answers the old ones? What should birth professionals understand and share with consumers about the evidence to induce at 39 weeks?
Author and evidence-based maternity care expert Henci Goer, a frequent Science & Sensibility contributor, examines the abstract of the ARRIVE Trial (the only published material from the study available at this time) and shares with S&S readers her careful examination of the study's conclusions.